This study was conducted as a field trial of using a new candidate trivalent Capripoxvirus (CaPVs) vaccine in pregnant ewes and does to detect safety degree and level of immunity, in comparison with commercial Romanian sheep pox viral (RSPPV) vaccine. Monitoring the post-vaccinal reaction and measurement of cellular and humoral immunity by evaluating the lymphocyte proliferation assay (LPA) and serum neutralization test (SNT), respectively, in addition to detect the acquired maternal immunity in new-born lambs and kids. The post-vaccine reaction in animals vaccinated with trivalent CaPVs vaccine was more noticeable than that vaccinated with RSPPV vaccine without significant difference (P-Value>0.05). In vitro, the evaluation of cellular and humoral immunity revealed that the animals vaccinated with trivalent vaccine can significantly induce lymphocyte proliferation response in addition to of high level of antibodies (Abs) in comparison to that vaccinated with RSPPV vaccine (P-Value <0.05) with peak titre of lymphocyteproliferation and Abs titre at 10th and 28th, respectively. Furthermore, the evaluation of maternal immunity in new-born lambs and kids from previously vaccinated dams with trivalent CaPVs and RSPPV vaccines by SNT was shown that the peak level of receiving immunity was appeared at 1st week after birth with increasing its level in lambs and kids of dams vaccinated with trivalent CaPVs vaccine than those of dams vaccinated with RSPPV vaccine with a significant difference in between (P-Value <0.05). The result of this study provide a good profile about a high immune response with a long level of maternal immunity provided with trivalent CaPVs vaccine in comparison to the RSPPV vaccine so toward about the preferable use of new vaccine to control infection with sheep and goat pox diseases. Trivalent CaPVs vaccine could be candidate to be used against lumpy skin disease (LSD) due to antigenic relationship between genus CaPVs strains.